Shareholders of Akebia Therapeutics, Inc. ( NASDAQ:AKBA ) will be pleased this week, given that the stock price is up... CAMBRIDGE, Mass. AP) — Akebia Therapeutics Inc. AKBA) on Thursday ...

AKEBIA THERAPEUTICS ($AKBA) posted quarterly earnings results on Thursday, March 13th. The company reported earnings of -$0.10 per share, missing estimates of -$0.08 ...

CAMBRIDGE, Mass., March 06, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA) today announced plans to release its financial results for the fourth quarter and full year ended ...

Akebia Therapeutics (AKBA) stock drops as the company disappoints with its Q4 earnings update despite revenue beats. Read more here.

Akebia delivered the Vafseo progress report as it posted $46.5 million in total fourth-quarter revenue for 2024, down from the $56.2 million haul it brought home for the period in 2023. For the ...

Commenting on the Vafseo launch, John P. Butler, Chief Executive Officer of Akebia (AKBA) said: “We believe Vafseo can be a new standard of care for the treatment of anemia due to chronic kidney ...